Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 3/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | CENPE | Q02224 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1880261 | 0.93 | XDH (0.48) | XDHS1PR1S1PR3POLBCENPE | |
| SCHEMBL2617483 | 0.82 | XDH (0.52) | XDHS1PR1S1PR3CENPEALDH1A1 | |
| SCHEMBL14449510 | 0.81 | POLB (0.52) | POLBCENPEMAPTALDH1A1HPGD | |
| SCHEMBL2630616 | 0.79 | ALDH1A1 (0.42) | XDHS1PR1S1PR3MAPTALDH1A1 | |
| SCHEMBL30488306 | 0.77 | XDH (0.54) | XDHS1PR1S1PR3MAPT | |
| SCHEMBL1807138 | 0.77 | XDH (0.54) | XDHS1PR1S1PR3MAPT | |
| SCHEMBL403398 | 0.76 | XDH (0.67) | XDHALDH1A1HPGD | |
| SCHEMBL30603423 | 0.76 | XDH (0.67) | XDHALDH1A1HPGD | |
| SCHEMBL28323507 | 0.76 | XDH (0.56) | XDHS1PR1S1PR3POLBALDH1A1 | |
| SCHEMBL2630564 | 0.76 | GAA (0.45) | XDHS1PR1S1PR3POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207340-B2 | Imidazopyridinyl benzamide mitotic kinesin inhibitors | CYTOKINETICS, INCORPORATED (US) | 2012-06-26 | — | — | US | disclosed |
| US-8163919-B2 | Imidazopyridinyl benzamide mitotic kinesin inhibitors | CYTOKINETICS, INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-7795448-B2 | Imidazoyl-benzamide anti-cancer agents | CYTOKINETICS, INCORPORATED (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090312365-A1 | Certain Chemical Entities, Compositions, and Methods | CYTOKINETICS, INC. | 2009-12-17 | — | — | US | disclosed |
| US-20090306127-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC | 2009-12-10 | — | — | US | disclosed |
| US-20090286841-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. | 2009-11-19 | — | — | US | disclosed |
| US-7618981-B2 | to treat cellular proliferative diseases, hyperplasias, solid tumor, cardiac hypertrophy, immune disorders and inflammation; modulators of one or more mitotic kinesins; N-(2-(2-dimethylamino-acetylamino)-1-{4-[8-(1-hydroxy-ethyl)-imidazo[1,2-a]pyridin-2-yl]-benzyl}-ethyl)-3-chloro-4-isopropoxy-benzamide | CYTOKINETICS, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-20080255182-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-10-16 | — | — | US | disclosed |
| US-20070197481-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-08-23 | — | — | US | disclosed |
| WO-2007056469-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306127-A1 | Certain Chemical Entities, Compositions and Methods | KIF5B, KIF2C, PLK1 | XDH 3409/4885S1PR1 2584/4885S1PR3 2464/4885 |
| US-20080255182-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | XDH 3591/4885S1PR1 2943/4885S1PR3 2814/4885 |
| US-20090286841-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | KIF5B, KIF2C, PLK1 | XDH 3591/4885S1PR1 2943/4885S1PR3 2814/4885 |
| US-20090312365-A1 | Certain Chemical Entities, Compositions, and Methods | KIF5B, KIF2C, PLK1 | XDH 3591/4885S1PR1 2943/4885S1PR3 2814/4885 |
| US-20070197481-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | XDH 3591/4885S1PR1 2943/4885S1PR3 2814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.